Sobi will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025. Research will include… read more.
The FDA has approved an expanded indication of Sanofi’s quadrivalent meningococcal vaccine MenQuadfi—for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W,… read more.
Sudden cardiac death is responsible for an unusually high proportion of deaths in male bodybuilders worldwide with the highest risk among professional bodybuilders, according to research published in… read more.
Purdue University’s College of Pharmacy is now home to the Center for Research Innovation in Biotechnology and the Clinical Drug Experience Knowledgebase, a comprehensive database of every active… read more.
Bavarian Nordic A/S announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for Vimkunya (recombinant, adsorbed) for… read more.
How can we reduce wait times for much needed hip and knee replacement surgery in Canada? Coordinated referral and team-based care models show promise, according to research published… read more.
Standardising the colour and branding of disposable vaping devices may deter young people who have never smoked or vaped from trying them in the first place, suggests a… read more.
Medtronic plc announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera family of technologies, including the next-generation Sphere-360 single-shot pulsed field… read more.
An observational study among 2,272 mother-child pairs in Finland found that infants had 44% lower odds of developing food allergies at 12 months if their mother consumed fresh… read more.
Women who choose to stop treatment during pregnancy and breastfeeding are putting their health at risk, and have to weigh their desire to have children and breastfeed against… read more.
Eli Lilly and Company announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American… read more.
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
